Cellectis SA • CLLS

Capital at risk.

About Cellectis SA
Ticker
info
CLLS
Trading on
info
NASDAQ
ISIN
info
US15117K1034
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Andre Choulika Ph.D.
Headquarters
info
8, rue de la Croix Jarry, Paris, undefined, France, 75013
Employees
info
224
Website
info
cellectis.com
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Metrics
BasicAdvanced
Market cap
info
$440M
P/E ratio
info
-
EPS
info
-$0.67
Dividend Yield
info
0.00%
Beta
info
2.71
Forward P/E ratio
info
0
EBIDTA
info
$-21.8M
Ex dividend date
info
-
Price & volume
Market cap
info
$440M
Average daily volume
info
0M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
5.53
Price to book
info
5.66
Earnings
EPS
info
-$0.67
EPS estimate (current quarter)
info
-$0.10
EPS estimate (next quarter)
info
-$0.18
EBITDA
info
$-21.8M
Revenues (TTM)
info
$79.6M
Revenues per share (TTM)
info
$0.79
Technicals
Beta
info
2.71
52-week High
info
$5.48
52-week Low
info
$1.33
50-day moving average
info
$3.64
200-day moving average
info
$3.54
Short ratio
info
6.71
Short %
info
0.65%
Management effectiveness
ROE (TTM)
info
-65.33%
ROA (TTM)
info
-5.84%
Profit margin
info
-84.92%
Gross profit margin
info
$79.6M
Operating margin
info
-142.14%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-19.50%
Share stats
Outstanding Shares
info
72.6M
Float
info
46.7M
Insiders %
info
-
Institutions %
info
16.96%
Analyst Insights & forecasts
info

60% Buy

40% Hold

0% Sell

Based on information from 5 analysts.

Average price target

info
$7.25
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.17
-$0.24
29.17%
Q1 • 25Beat
-$0.24
-$0.20
-20.00%
Q2 • 25Missed
$0.01
-$0.23
104.28%
Q3 • 25Beat
-$0.24
-$0.29
18.59%
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$35.2M
$0.6M
1.67%
Q3 • 25
$10.4M
$-26.3M
-252.97%
Q4 • 25
-70.44%
-4,564.94%
-15,205.90%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$343M
$243M
70.71%
Q3 • 25
$325M
$249M
76.63%
Q4 • 25
-5.34%
2.58%
8.37%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-1.6M
$-3.4M
$-4.3M
$-2.8M
Q3 • 25
$-10.5M
$22.9M
$-4M
$-11M
Q4 • 25
566.67%
-766.72%
-5.42%
297.96%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cellectis SA share?
Collapse

Cellectis SA shares are currently traded for undefined per share.

How many shares does Cellectis SA have?
Collapse

Cellectis SA currently has 72.6M shares.

Does Cellectis SA pay dividends?
Collapse

No, Cellectis SA doesn't pay dividends.

What is Cellectis SA 52 week high?
Collapse

Cellectis SA 52 week high is $5.48.

What is Cellectis SA 52 week low?
Collapse

Cellectis SA 52 week low is $1.33.

What is the 200-day moving average of Cellectis SA?
Collapse

Cellectis SA 200-day moving average is $3.54.

Who is Cellectis SA CEO?
Collapse

The CEO of Cellectis SA is Dr. Andre Choulika Ph.D..

How many employees Cellectis SA has?
Collapse

Cellectis SA has 224 employees.

What is the market cap of Cellectis SA?
Collapse

The market cap of Cellectis SA is $440M.

What is the P/E of Cellectis SA?
Collapse

The current P/E of Cellectis SA is null.

What is the EPS of Cellectis SA?
Collapse

The EPS of Cellectis SA is -$0.67.

What is the PEG Ratio of Cellectis SA?
Collapse

The PEG Ratio of Cellectis SA is 0.

What do analysts say about Cellectis SA?
Collapse

According to the analysts Cellectis SA is considered a buy.